- Home
- GAME vs CING Comparison
GAME vs CING Comparison
Compare GAME & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | CING |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 40.5M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GAME | CING |
|---|---|---|
| Price | $0.44 | $5.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 1.3M | 196.2K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,810,388.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 188.95 | N/A |
| 52 Week Low | $0.37 | $3.20 |
| 52 Week High | $2.87 | $6.01 |
Technical Indicators
Market Signals| Indicator | GAME | CING |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 74.12 |
| Support Level | $0.43 | $4.83 |
| Resistance Level | $0.48 | $5.07 |
| Average True Range (ATR) | 0.03 | 0.42 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 57.76 | 94.57 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.